The goal is to identify new disease
diagnostic markers and
develop new therapies, according to the company's head of R&D in China, Andreas Tschirky, and chief scientific officer Li Chen.
TRIB also acquired Fiomi
Diagnostics, a Swedish company at an advanced stage in
developing a panel of point - of - care cardiac
marker assays, particularly for Troponin I. $ 60 mio «s already been spent on the technology, and it offers TRIB a slice of the $ 900 mio Cardiac POC
diagnostics market, which is growing 14 % pa.